Teduglutide in Short Bowel Syndrome Patients
Completed
- Conditions
- Short Bowel Syndrome
- Registration Number
- NCT04857801
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
A retrospective analysis was performed using data of patients suffering from non-malignant SBS-IF. They were treated with teduglutide in a multidisciplinary SBS-IF program at a single university medical center between June 2016 and June 2020.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
- SBS-IF
Exclusion Criteria
- < 18 years
- Incompliance
- < 6 months of treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method enteral autonomy at least 6 months of teduglutide treatment percentage of patients reaching complete discontinuation of parenteral support
- Secondary Outcome Measures
Name Time Method